<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117010</url>
  </required_header>
  <id_info>
    <org_study_id>2016-08-117</org_study_id>
    <nct_id>NCT03117010</nct_id>
  </id_info>
  <brief_title>Prospective Cohort for Adult Hemophagocytosis</brief_title>
  <official_title>A Prospective Cohort for Subjects With Adult Hemophagocytic Lymphohistiocytosis Like Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study enrolls subjects who have clinical and laboratory manifestations
      related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate
      clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled
      subjects into this study will be evaluated according to the HLH (hemophagocytic
      lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or
      chemotherapy. All subjects will be regularly monitored by physicians participating in this
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study process is as follows.

        1. Informed consent for subjects fulfilling the inclusion criteria.

        2. Laboratory evaluation will be done for subjects according to the following diagnostic
           criteria.

             -  Diagnosis will be established if one of either 1 or 2 below is fulfilled

                  1. A molecular diagnosis consistent with HLH

                  2. Diagnostic criteria for HLH fulfilled (5 out of 8 criteria below)

             -  fever ≥ 38.5'C for ≥ 7 days

             -  splenomegaly ≥ 3 finger breadth below left subcostal margin

             -  cytopenias affecting ≥2 of 3 lineages in peripheral blood (Hemoglobin &lt; 9 g/L,
                Platelets &lt; 100 × 109/L, Absolute neutrophil count &lt; 1.0 × 109/L)

             -  Hypertriglyceridemia and/or hypofibrinogenemia: Fasting triglycerides ≥ 265 mg/dL,
                fibrinogen ≤ 1.5 g/L

             -  Hemophagocytosis in bone marrow or spleen or lymph node

             -  Low or absent NK-cell activity (according to local laboratory reference)

             -  Ferritin ≥ 500 mcg/L

             -  Soluble CD25 (sIL-2 receptor) ≥ 2,400 U/mL
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>28 days after the 1st treatment</time_frame>
    <description>Response to steroids and etoposide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time to date of progression or any kinds of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time to date of any kinds of death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Hemophagocytic Lymphohistiocytoses</condition>
  <arm_group>
    <arm_group_label>Hemophagocytosis</arm_group_label>
    <description>Subjects should fulfill the following criteria
Subjects should have at least one of the following problems
Presence of hemophagocytosis in tissue or bone marrow
Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria
Age &gt; 18 years
Written informed consents
Subjects receive steroids and etoposide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>High dose dexamethasone 20 mg PO or IV</description>
    <arm_group_label>Hemophagocytosis</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide 150mg/BSA</description>
    <arm_group_label>Hemophagocytosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Serum sample collection will be done as follows: Baseline, 4 weeks after treatment,
           Relapse or progression

        2. Germline DNA collection from peripheral blood will be done at the enrollment
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have clinical and laboratory manifestations related with hemophagocytic
        lymphohistiocytosis.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects should fulfill the following criteria

               1. Subjects should have at least one of the following problems

                    1. Presence of hemophagocytosis in tissue or bone marrow

                    2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic
                       criteria

               2. Age &gt; 18 years

               3. Written informed consents

                  Exclusion Criteria:

          -  Subjects cannot satisfy the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok Jin Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seok Jin Kim, MD, PhD</last_name>
    <phone>+82234101766</phone>
    <email>kstwoh@skku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Park, MD, PhD</last_name>
    <phone>+82234103459</phone>
    <email>silvia.park@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok Jin Kim, MD, PhD</last_name>
      <phone>82-2-3410-1766</phone>
      <email>kstwoh@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Seok Jin Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Won Seog Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophagocytic lymphohistiocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

